Weill Cornell's HER2 presentation could change breast cancer treatment forever

In the United States, at the San Antonio Breast Cancer Symposium, Weill Cornell Medicine presented findings independent of ANGLE plc that support the company's HER2 assay development program. The presentation detailed a study involving 16 patients with metastatic breast cancer, during which ANGLE's Parsortix system was employed to isolate Circulating Tumor Cells (CTCs) and analyze their HER2 status. The study found that the Parsortix system successfully identified CTCs in all patients and classified their HER2 status, demonstrating the potential for using this technology in personalized treatment plans. The research highlighted the need for a minimally invasive, real-time assay capable of accurately monitoring HER2 status over time. This is crucial since HER2 expression can change significantly in up to 38% of breast cancer patients, impacting their eligibility for treatments involving HER2 antibody drug conjugates (ADCs). The ability to assess HER2 dynamically can facilitate timely treatment interventions, aligning patient care with evolving cancer characteristics. Karen Miller, ANGLE's Chief Scientific Officer, expressed optimism about the new data supporting the quantitative assessment of HER2 on CTCs. The results not only validate ANGLE's previous findings but also signal potential improvements in breast cancer patient stratification for clinical trials. Additionally, the work points toward innovative methodologies that could be applied to various biomarkers beyond HER2, with an ultimate goal of developing automated workflows for longitudinal CTC analysis. ANGLE's Parsortix system is an FDA-cleared technology that allows for extensive downstream analyses including genomic and proteomic studies. With over 100 peer-reviewed publications demonstrating its efficacy, the Parsortix system is positioned to be a vital tool in the fight against cancer, providing insights that could revolutionize treatment paradigms by ensuring that patients receive therapies tailored to their specific cancer profiles.